Profile data is unavailable for this security.
About the company
Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
- Revenue in USD (TTM)0.00
- Net income in USD-157.24m
- Incorporated2017
- Employees136.00
- LocationEdgewise Therapeutics Inc1715 38Th StBOULDER 80301United StatesUSA
- Phone+1 (720) 262-7002
- Fax+1 (302) 636-5454
- Websitehttps://edgewisetx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dyne Therapeutics Inc | 0.00 | -423.80m | 2.70bn | 240.00 | -- | 3.44 | -- | -- | -3.66 | -3.66 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -51.81 | -57.98 | -55.30 | -63.58 | -- | -- | -- | -- | -- | -- | 0.1254 | -- | -- | -- | -34.54 | -- | 7.60 | -- |
| Travere Therapeutics Inc | 435.83m | -88.54m | 2.70bn | 385.00 | -- | 36.75 | -- | 6.20 | -1.08 | -1.08 | 4.80 | 0.8223 | 0.8357 | 1.74 | 8.06 | 1,132,018.00 | -16.98 | -41.64 | -24.67 | -51.97 | 97.63 | 95.90 | -20.32 | -175.36 | 2.71 | -- | 0.8089 | -- | 60.55 | 5.87 | 14.80 | -- | 45.42 | -- |
| Disc Medicine Inc | 0.00 | -181.11m | 2.72bn | 84.00 | -- | 4.40 | -- | -- | -5.35 | -5.35 | 0.00 | 16.38 | 0.00 | -- | -- | 0.00 | -32.18 | -- | -33.75 | -- | -- | -- | -- | -- | -- | -- | 0.0481 | -- | -- | -- | -43.08 | -- | -- | -- |
| Ideaya Biosciences Inc | 214.83m | -160.74m | 2.80bn | 131.00 | -- | 2.56 | -- | 13.02 | -1.85 | -1.85 | 2.43 | 12.46 | 0.1772 | -- | -- | 1,639,954.00 | -13.26 | -22.71 | -13.86 | -24.48 | -- | -- | -74.82 | -411.78 | -- | -- | 0.00 | -- | -70.07 | -- | -142.98 | -- | 23.31 | -- |
| Veracyte Inc | 495.14m | 30.32m | 2.84bn | 824.00 | 94.94 | 2.26 | 54.00 | 5.75 | 0.3791 | 0.3791 | 6.21 | 15.91 | 0.3747 | 7.66 | 10.25 | 600,899.30 | 2.29 | -4.19 | 2.43 | -4.43 | 68.53 | 66.82 | 6.12 | -13.70 | 5.94 | -- | 0.00 | -- | 23.46 | 29.93 | 132.44 | -- | 32.57 | -- |
| Viridian Therapeutics Inc | 70.79m | -301.97m | 2.87bn | 143.00 | -- | 7.87 | -- | 40.54 | -3.72 | -3.72 | 0.8716 | 6.12 | 0.105 | -- | 2.02 | 495,028.00 | -44.77 | -50.26 | -48.05 | -53.97 | -- | -- | -426.58 | -12,930.56 | -- | -- | 0.0399 | -- | -3.82 | -41.64 | -13.55 | -- | 43.49 | -- |
| Vera Therapeutics Inc | 0.00 | -251.94m | 3.01bn | 224.00 | -- | 6.88 | -- | -- | -3.98 | -3.98 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -56.87 | -54.55 | -61.62 | -60.06 | -- | -- | -- | -- | -- | -- | 0.1576 | -- | -- | -- | -58.50 | -- | 50.71 | -- |
| Denali Therapeutics Inc | 0.00 | -498.74m | 3.07bn | 517.00 | -- | 3.12 | -- | -- | -2.91 | -2.91 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -39.75 | -16.91 | -42.77 | -19.81 | -- | -- | -- | -135.24 | -- | -- | 0.006 | -- | -100.00 | -- | -191.12 | -- | -2.35 | -- |
| Alumis Inc | 22.12m | -245.15m | 3.19bn | 233.00 | -- | 6.95 | -- | 144.43 | -3.85 | -3.85 | 0.3057 | 3.69 | 0.0491 | -- | 9.28 | 131,672.60 | -54.44 | -- | -61.16 | -- | -- | -- | -1,108.24 | -- | -- | -- | 0.00 | -- | -- | -- | -89.84 | -- | -- | -- |
| Viking Therapeutics Inc | 0.00 | -237.39m | 3.23bn | 50.00 | -- | 4.50 | -- | -- | -2.12 | -2.12 | 0.00 | 6.34 | 0.00 | -- | -- | 0.00 | -28.31 | -22.44 | -29.21 | -23.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -28.02 | -- | -- | -- |
| Edgewise Therapeutics Inc | 0.00 | -157.24m | 3.25bn | 136.00 | -- | 5.80 | -- | -- | -1.58 | -1.58 | 0.00 | 5.28 | 0.00 | -- | -- | 0.00 | -28.73 | -26.21 | -29.83 | -27.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.60 | -- | 48.78 | -- |
| Xenon Pharmaceuticals Inc | 7.50m | -306.33m | 3.30bn | 316.00 | -- | 5.89 | -- | 440.57 | -3.88 | -3.88 | 0.0952 | 7.26 | 0.0104 | -- | 8.57 | 23,734.18 | -42.44 | -22.00 | -44.53 | -22.93 | -- | -- | -4,084.45 | -1,082.36 | -- | -- | 0.00 | -- | -- | -- | -28.48 | -- | 19.92 | -- |
| Legend Biotech Corp (ADR) | 908.96m | -239.70m | 3.42bn | 2.90k | -- | 3.39 | -- | 3.77 | -1.30 | -1.30 | 4.94 | 5.48 | 0.5271 | 13.60 | 936.59 | 349,601.20 | -13.90 | -30.18 | -17.47 | -36.54 | 60.55 | -- | -26.37 | -154.41 | 2.80 | -1.36 | 0.2886 | -- | 119.97 | 59.91 | 65.84 | -- | -18.48 | -- |
| Erasca Inc | 0.00 | -127.69m | 3.58bn | 103.00 | -- | 9.43 | -- | -- | -0.4506 | -0.4506 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -26.90 | -41.53 | -28.68 | -44.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.28 | -- | -36.84 | -- |
| ACADIA Pharmaceuticals Inc | 1.05bn | 261.17m | 3.80bn | 653.00 | 14.47 | 4.14 | 13.81 | 3.63 | 1.55 | 1.55 | 6.21 | 5.42 | 0.9075 | 1.88 | 9.78 | 1,603,550.00 | 22.64 | -13.15 | 32.50 | -16.74 | 91.92 | 94.49 | 24.94 | -16.00 | 2.94 | -- | 0.00 | -- | 31.85 | 23.08 | 469.50 | -- | -14.26 | -- |
Data as of Feb 11 2026. Currency figures normalised to Edgewise Therapeutics Inc's reporting currency: US Dollar USD
50.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Sep 2025 | 10.43m | 9.85% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 7.31m | 6.90% |
| Paradigm BioCapital Advisors LPas of 30 Sep 2025 | 6.17m | 5.83% |
| Braidwell LPas of 30 Sep 2025 | 5.21m | 4.92% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 5.08m | 4.80% |
| Janus Henderson Investors US LLCas of 30 Sep 2025 | 4.91m | 4.64% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.28m | 4.04% |
| Cormorant Asset Management LPas of 30 Sep 2025 | 4.01m | 3.79% |
| Perceptive Advisors LLCas of 30 Sep 2025 | 3.80m | 3.59% |
| Bellevue Asset Management AGas of 30 Sep 2025 | 2.78m | 2.62% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
